ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 156 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,055,262 | +272.5% | 631,626 | +613.6% | 0.02% | +214.3% |
| Q2 2023 | $1,894,221 | -60.4% | 88,515 | -25.2% | 0.01% | -58.8% |
| Q1 2023 | $4,786,357 | +196223.1% | 118,357 | +125.8% | 0.02% | +88.9% |
| Q4 2022 | $2,438 | -99.8% | 52,411 | +127.3% | 0.01% | +80.0% |
| Q3 2022 | $1,196,000 | -81.6% | 23,058 | -83.2% | 0.01% | -79.2% |
| Q2 2022 | $6,489,000 | -32.6% | 137,266 | +1.5% | 0.02% | -11.1% |
| Q1 2022 | $9,623,000 | +15.4% | 135,186 | +21.3% | 0.03% | +12.5% |
| Q4 2021 | $8,337,000 | +54.2% | 111,483 | +17.2% | 0.02% | +41.2% |
| Q3 2021 | $5,405,000 | +650.7% | 95,149 | +481.7% | 0.02% | +750.0% |
| Q2 2021 | $720,000 | -88.5% | 16,357 | -88.0% | 0.00% | -94.3% |
| Q3 2020 | $6,235,000 | +154.4% | 136,204 | +179.0% | 0.04% | +118.8% |
| Q2 2020 | $2,451,000 | – | 48,823 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |